The thoracic oncology session at the 2024 ESMO Asia Annual Meeting featured prominent oral presentations, focusing on thymic tumors and non-small cell lung cancer (NSCLC). Key studies included the Phase II MARBLE trial (Abstract LBA8) evaluating atezolizumab combined with carboplatin/paclitaxel for metastatic or recurrent thymic carcinoma and the Phase II AL3810-202 trial (Abstract 6250) assessing Lucitanib (Delitinib, AL3810) as a second-line or subsequent therapy for advanced recurrent or metastatic thymic carcinoma.

Previous studies have demonstrated that short-term efficacy metrics, such as objective response rate (ORR), are associated with long-term survival outcomes, such as overall survival (OS), in targeted therapy for advanced hepatocellular carcinoma (HCC). At the 2024 International Liver Cancer Association (ILCA) Conference, Professor Masatoshi Kudo from Kinki University Faculty of Medicine in Japan presented exploratory analyses on the correlation between efficacy metrics like depth of response (DpR) and duration of response (DoR) with OS benefits. He also discussed their value in guiding systemic drug therapy combined with local treatments. We interviewed Professor Kudo to share his key findings.

The 2024 European Society for Medical Oncology Asia Congress (ESMO Asia 2024) was held in Singapore from December 6 to 8. In the session featuring selected oral presentations on thoracic oncology, Professor  Wentao Fang from Shanghai East Hospital, Tongji University presented findings from the AL3810-202 trial (Abstract 625O), which evaluated Lucitanib (Delitinib, AL3810) as a second-line or subsequent therapy for advanced recurrent or metastatic thymic carcinoma. During the conference, Oncology Frontier invited Professor Fang to discuss the study findings and share highlights from the event.

The European Society for Medical Oncology Asia (ESMO Asia) Congress was held in Singapore，from 6 to 8 December 2024. ESMO Asia is an annual congress specifically focused on multidisciplinary oncology in the Asian region, providing a remarkable platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field. During the three-day event, Qilu Pharmaceutical unveiled the latest findings from three key studies on iparomlimab and tuvonralimab (QL1706), a bifunctional MabPair® product of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.

With the continuous progress in the field of breast cancer treatment, precision medicine is gradually becoming the key to improving treatment outcomes. At the 2024 ESMO ASIA Annual Meeting, Prof. Biyun Wang from Fudan University Shanghai Cancer Center delivered a proffered oral presentation in the "Proffered Paper session: Breast cancer" session, introducing to colleagues around the world the latest research findings of her team in screening and guiding first-line treatment of HR+/HER2- metastatic breast cancer with 18F-FES PET/CT. After the presentation, Oncology Frontier specially invited Professor Wang Biyun for an interview. She provided us with a detailed interpretation of the background, significance, challenges, and innovation points of this study, and also looked forward to the research directions in the field of HR+/HER2- breast cancer treatment in the future, hoping to provide valuable references and inspiration for the majority of clinicians and researchers.